EXHIBIT 10.13
DEVELOPMENT AND MANUFACTURING
SERVICE AGREEMENT
BETWEEN
LONZA BIOLOGICS PLC
AND
TRUBION PHARMACEUTICALS, INC.
CONFIDENTIAL TREATMENT
TABLE OF CONTENTS
PAGE
----
1. Definitions......................................................................... 3
2. Customer Obligations, Warranties and Indemnities.................................... 10
3. Provision of the Services........................................................... 12
4. Quality; Project Management......................................................... 15
5. Delivery, Transportation of Product and Customer Tests.............................. 17
6. Price and Terms of Payment.......................................................... 19
7. LB Warranties and Covenants and Indemnity........................................... 19
8. Confidentiality and Non-Use......................................................... 21
9. Termination; Ownership; License Rights.............................................. 23
10. Force Majeure....................................................................... 28
11. Governing Law, Jurisdiction and Enforceability; Dispute Resolution.................. 28
12. Notices............................................................................. 29
13. Miscellaneous....................................................................... 30
14. Limitation of Liability; Exclusion of Certain Damages............................... 31
CONFIDENTIAL TREATMENT
2
THIS AGREEMENT is made effective as of the 8th day of January 2004 (the
"Effective Date") BETWEEN
1. LONZA BIOLOGICS PLC, the registered office of which is at 000 Xxxx
Xxxx, Xxxxxx, Xxxxxxxxx XX0 0XX, Xxxxxxx (herein after referred to as "LB"), and
2. TRUBION PHARMACEUTICALS, INC., (formerly known as GENECRAFT, INC.) of
24014th Avenue, Suite 1050, Xxxxxxx, XX 00000, XXX (herein after referred to as
the "Customer").
WHEREAS
A. The Customer has created or controls certain Cell Lines as defined
herein; and
B. LB has expertise in the evaluation and production of proteins for
therapeutic use using such Cell Lines; and
C. The Customer wishes to contract LB for Services as defined herein
relating to the Cell Line as described in the Agreement; and
D. LB is prepared to perform such Services for the Customer under the
terms and conditions set out herein.
NOW IT IS AGREED AS FOLLOWS:
1. DEFINITIONS. The following terms shall have the following meanings:
"Affiliate" means any company, partnership or other entity
which directly or indirectly Controls, is
Controlled by or is under common Control with the
relevant party to this Agreement. "Control" means
the ownership of more than fifty per cent (50%) of
the issued share capital or the legal power to
direct or cause the direction of the general
management and policies of the party in question.
"Agreement" means this agreement, including and incorporating
Schedule 1 (Definitions and Specifications),
Schedule 2 (Services), Schedule 3 (Price and Terms
of Payment), Schedule 4 (Quality Agreement), and
Schedule 5 (Commercial Terms for Technology
Transfer), all as the same may be amended or
varied from
CONFIDENTIAL TREATMENT
3
time to time by written agreement of the parties.
"August 2003 Services means that certain development and manufacturing
Agreement" agreement dated 12 August 2003 between the parties
for the development and manufacture of the
Product, as amended or varied from time to time by
written agreement of the parties.
"Batch" means the total quantity of Manufactured Product
obtained from one fermentation and associated
purification run using the Process.
"Cell Line" means the cell line provided by Customer to LB,
the particulars of which are set out in
Schedule 1.
"cGMP" means the regulatory requirements for current Good
Manufacturing Practices and General Biologics
Products Standards as promulgated by the United
States Food and Drug Administration ("FDA") (or
any successor agency thereto) under the United
States Federal Food Drug and Cosmetic Act and the
Public Health Service Act, at 21 CFR (Parts 210,
211, 600 and 610), and the Guide to Good
Manufacturing Practices for Medicinal Products as
promulgated under European Directive 91/356/EEC,
all as the same may be amended from time to time.
"cGMP Product" means Product which is required under Schedule 2
to be manufactured in accordance with cGMP.
"Certificate of means, for each Batch, a document in a format
Analysis" agreed to by the parties and prepared by LB
listing (a) the date of manufacturing, unique
Batch number, tests performed, Specifications,
test dates, and test results, (b) the quantity of
Manufactured Product in such Batch, and certifying
that such Batch was manufactured in accordance
with the Specifications and cGMP, and (c) the
tests performed by LB or permitted Testing
Laboratories, Specifications, and test results;
all with respect to such particular Batch
CONFIDENTIAL TREATMENT
4
and as required by the Specifications, the
accuracy of which has been certified by LB.
"Critical Raw has the meaning given to it in Clause 4.6 below.
Materials"
"Customer" means Trubion Pharmaceuticals, Inc., and its
successors in title and lawful assigns.
"Customer Information" means (a) all Customer Know-How and other
tangible and intangible data, information, and
know-how, whether in written, printed, graphic,
electronic, or oral form, supplied by or on
behalf of Customer to LB hereunder or under the
August 2003 Services Agreement; (b) all
Documentation and all tangible and intangible
data, information, know-how, and Intellectual
Property included in the Documentation; (c) all
Deliverables and all tangible and intangible data,
information, know-how, and Intellectual Property
included in the Deliverables; and (d) all tangible
and intangible data, information, know-how, and
Intellectual Property included in the Customer
Process; "Customer Information" does not include
LB Know-How, the LB Patent Rights, the LB Process,
the New General Application Intellectual Property,
and LB's other Intellectual Property, "Customer
Information" is a part of "Customer Technology."
"Customer Know-How" means all know-how, technical and other
information relating directly or indirectly to the
Cell Line, the Customer Process (including for the
avoidance of doubt improvements or modifications
thereto from time to time, other than and
excluding the LB Process and any New General
Application Intellectual Property), Customer's
business, technology, finances or operations,
trade secrets, the Customer Materials, and/or the
Product, known by Customer from time to time;
"Customer Know-How" does not include LB Know-How,
the LB Patent Rights the LB Process, the New
General Application Intellectual Property, LB's
other Intellectual Property, and information in
the
CONFIDENTIAL TREATMENT
5
public domain; "Customer Know-How" is a part of
"Customer Information."
"Customer Materials" means the materials (if any) supplied by Customer
to LB pursuant to this Agreement.
"Customer Patent means all patents and patent applications,
Rights" together with any extensions, reissues,
reexaminations, substitutions, renewals,
divisions, continuations, and
continuations-in-part thereof, of any kind
throughout the world that are necessary or useful
in performance of the Services, which from time to
time Customer is the owner of or entitled to use,
other than and excluding the LB Patent Rights.
"Customer Process" means that portion of the Process not composed
of or included within the LB Process, including
without limitation all processes, procedures,
protocols, know-how, technology, information and
Intellectual Property developed by LB and/or
Customer specifically with respect to manufacture
of the Product under or as a result of this
Agreement or the August 2003 Services Agreement;
"Customer Process" does not include LB Know-How,
the LB Patent Rights, the LB Process, the New
General Application Intellectual Property, or LB's
other Intellectual Property.
"Customer Technology" means all data, information, know-how, materials,
and Intellectual Property which from time to time
Customer is the owner of or entitled to use,
including without limitation the Customer
Know-How, the Customer Patent Rights, the Cell
Line, the Customer Materials, the Customer
Information, the Customer Process, the New
Customer Intellectual Property, and the Product;
"Customer Technology" does not include LB
Know-How, the LB Patent Rights, the LB Process,
the New General Application Intellectual Property,
LB's other Intellectual Property, and information
in the public domain.
CONFIDENTIAL TREATMENT
6
"Deliver", "Delivered" has the meaning given to it in Clause 5.1 below,
or "Delivery"
"Deliverables" means the data, information, material, reports,
Documentation, Product, samples and other items
that LB is obligated to provide to the Customer
under the terms of the Services, as set forth in
Schedule 2.
"Documentation" means all data, information and materials,
whether in written, printed, graphic, or
electronic form, resulting from the work conducted
and/or results achieved in connection with the
Services, including without limitation documents
reasonably necessary for Customer to complete any
regulatory filings for the Product;
"Documentation" does not include LB Know-How, the
LB Patent Rights, the LB Process, the New General
Application Intellectual Property, and LB's other
Intellectual Property; "Documentation" is a part
of "Customer Information."
"Intellectual Property" means proprietary methods, discoveries,
inventions, patents, trade secrets, copyrights,
trademarks, service marks, trade dress,
compositions, products, procedures, know-how,
data, reports, programs, processes, protocols,
written or electronic writings, illustrations,
images, and any other form of proprietary rights,
and, as the context requires, includes, among
other things, the Customer Know-How, the Customer
Patent Rights, the Customer Process, the New
Customer Intellectual Property, the LB Know-How,
the LB Patent Rights, the LB Process and the New
General Application Intellectual Property.
"LB Know-How" means all know-how, technical and other
information relating directly or indirectly to the
LB Patent Rights, the LB Process (including for
the avoidance of doubt improvements; or
modifications thereto from time to time, other
than and excluding the Customer Process and any
New Customer Intellectual Property) LB's
CONFIDENTIAL TREATMENT
7
business, technology, finances or operations, and
trade secrets known to LB from time to time; "LB
Know-How" does not include the Customer Patent
Rights, the Customer Know-How, the New Customer
Intellectual Property, the Customer Process,
Customer's other Intellectual Property, and
information in the public domain.
"LB Patent Rights" means all patents and patent applications,
together with any extensions, reissues,
reexaminations, substitutions, renewals,
divisions, continuations, and
continuations-in-part thereof, of any kind
throughout the world relating to the LB Process
which from time to time LB is the owner of or is
entitled to use; "LB Patent Rights" does not
include the Customer Patent Rights and the New
Customer Intellectual Property and Customer's
other Intellectual Property.
"LB Process" means the manufacturing process for proteins that,
as of the Effective Date, is included within the
LB Patent Rights and LB Know-How, along with any
New General Application Intellectual Property, as
defined herein in Clause 9.8.2.
"Legal Requirements" means any and all laws, rules, regulations,
ordinances, guidelines, and standards of any
international, national, state, or local
governmental authority, applicable to LB, the
Services, the Product, or any facility at which
any of the Services are performed, including
without limitation (a) cGMP, and (b) all laws and
regulations requiring permits, licenses, filings
and certifications with respect to LB, the
Services, the Product, or any facility at which
any of the Services are performed.
"Manufactured Product" means any and all tangible forms of the Product
which are manufactured under this Agreement using
the Process, including without limitation all
in-process intermediates, samples and derivatives
thereof.
CONFIDENTIAL TREATMENT
8
"New Customer
Intellectual Property" has the meaning given to it in Clause 9.8.3.
"New General Application
Intellectual Property" has the meaning given to it in Clause 9.8.2.
"Price" means the price specified in Schedule 3 for the
Services.
"Process" means the process for the production of the
Product from the Cell Line pursuant to this
Agreement, which is composed of the LB Process and
the Customer Process, and including any
improvements, changes or modifications to such
process from time to time.
"Product" means the proprietary Small Modular
ImmunoPharmaceutical (SMIP) known as TRU-015,
including any derivatives and improvements
thereof; and, when the context requires, the term
"Product" also means and refers any and all
tangible forms of the Product which are
manufactured under this Agreement using the
Process, including without limitation all
in-process intermediates, samples, derivatives,
and improvements thereof.
"Quality Agreement" means and refers to the quality agreement between
the parties, a copy of which is attached hereto as
Schedule 4, as amended or varied from time to time
by written agreement of the parties;
"Run" or "run" means a single fermentation start of the
manufacturing Process at LB's facility.
"Services" means all or any part of the services to be
performed by LB under this Agreement (including,
without limitation, cell culture evaluation,
purification evaluation, master, working and
extended cell bank creation, sample and bulk
production, testing of finished Product after
fill-finish processing of bulk Product at a third
party facility), as more particularly set out in
Schedule 2.
CONFIDENTIAL TREATMENT
9
"Specialized Raw
Materials" has the meaning given to it in Clause 3.10 below.
"Specifications" means the quality, functional and analytical
specifications for Product, the particulars of
which are set out in Schedule 1.
"Terms of Payment" means the terms of payment specified in Schedule
3.
"Testing Laboratories" means any third party who has been instructed by
LB and authorized by Customer to carry out tests
on the Cell Line or the Product.
References to the singular number include the plural and vice versa, references
to Clauses and Schedules are references to clauses and schedules to this
Agreement.
2. CUSTOMER OBLIGATIONS, WARRANTIES AND INDEMNITIES
2.1 Customer shall pay the Price set out in Schedule 3 for provision
of the Services together with any additional costs and expenses mutually agreed
upon in writing by the parties that fall due under this Agreement in accordance
with the Terms of Payment.
2.2 As agreed by the parties, the Customer shall supply to LB
certain Customer Know-How, together with full details of any hazards known to
Customer relating to the Cell Line and/or the Customer Materials, and their
storage and use. On review of this Customer Know-How by LB, the Cell Line and/or
the Customer Materials shall be provided to LB at LB's request, all as set forth
with more particularity in and in accordance with Schedule 2 (Services) hereto.
All right, title, and interest in and to the Cell Line, the Customer Materials,
the Customer Know-How and any other Customer Technology supplied to LB in
connection with this Agreement or the August 2003 Services Agreement shall, as
between the parties, remain vested in the Customer. Risk of loss to the Cell
Line, Customer Materials and any tangible Customer Information supplied to LB
under this Agreement shall transfer to LB upon delivery to LB premises.
2.3 Subject to the terms and conditions of this Agreement, the
Customer hereby grants LB the non-exclusive, non-transferable (other than to
LB's Affiliates), right to use the Cell Line, the Customer Materials, the
Customer Know-How, and the New Customer Intellectual Property during the term of
this Agreement solely for the purpose of providing Services under this
Agreement. The Customer warrants and covenants to LB that:
2.4.1 Customer has the right to enter into this Agreement;
2.4.2 ***;
CONFIDENTIAL TREATMENT
10
2.4.3 ***;
2.4.4 ***;
2.4.5 Customer will promptly notify LB in writing if it
receives or is notified of a lawsuit that has been filed against Customer which
includes a claim from a third party that the Cell Line, other Customer
Materials, Customer Know-How, Customer Patent Rights, Customer Process, or New
Customer Intellectual Property infringes any intellectual property rights of
such third party or that the use by LB thereof for the provision of the Services
infringes any intellectual property rights of such third party; and
2.4.6 ***.
2.5 Subject to Clauses 2.8 and 14 below, and subject to and except
to the extent of any indemnification from LB pursuant to Clause 7 below, the
Customer undertakes to indemnify and to maintain LB promptly indemnified against
all losses, damages, liabilities, settlements, penalties, fines, costs and
expenses of any nature (including court costs and reasonable legal fees on a
full indemnity basis), that LB may incur to the extent such liabilities arise
directly out of or result from any claim, lawsuit or other action by a third
party arising out of or resulting from any breach of any of the warranties given
by the Customer under Clause 2.4 above..
2.6 Subject to Clauses 2.8 and 14 below, and subject to and except
to the extent of any indemnification from LB pursuant to Clause 7 below, the
Customer shall further indemnify and maintain LB promptly indemnified against
all losses, damages, liabilities, settlements, penalties, fines, costs and
expenses of any nature (including court costs and reasonable legal fees on a
full indemnity basis), that LB may incur arising out of or resulting from:
2.6.1 any product liability in respect of Product, unless such
liability is caused by the negligent act or omission or willful misconduct of
LB, including without limitation in the production and/or supply of Product; and
2.6.2 any negligent act or omission or willful misconduct of
the Customer in relation to the use, further processing, storage or sale of the
Product.
2.7 A party that intends to claim indemnification under this
Agreement (the "Indemnitee") shall promptly notify the indemnifying party (the
"Indemnitor") in writing of any third party claim, suit or proceeding included
within the scope of the indemnification) described in Clauses 2 or 7 hereunder
(each a "Claim") with respect to which the Indemnitee intends to claim such
indemnification, and shall tender the defense of such Claim to the Indemnitor,
and the Indemnitor shall have sole control of the defense and/or settlement of
such Claim. An Indemnitee hereunder shall have the right to retain its own
counsel, subject to the following conditions: (a) the Indemnitee's counsel's
role shall be limited to monitoring the Claim and performing a watching brief of
the Claim and the Indemnitee's counsel shall have no right to actively
participate in the defense and/or settlement of such Claim; and (b) the
Indemnitor shall have the right to veto the Indemnitee's selection of counsel,
acting reasonably and having provided substantive justification
CONFIDENTIAL TREATMENT
11
for such veto. So long as the foregoing conditions are met, the Indemnitor shall
bear the reasonable costs and expenses of one attorney acting as the
Indemnitee's counsel in accordance with this Clause 2.7, subject to the
following additional conditions: (x) the attorney's hourly rate must be
reasonable and cannot exceed the prevailing rate, based on the venue of the
claim, suit or proceeding; and (y) the Indemnitor shall have the right to review
and approve the Indemnitee's counsel's invoices. The indemnification obligations
under this Agreement shall not apply to amounts paid in settlement of any Claim
if such settlement is effected without the consent of the Indemnitor, such
consent not to be unreasonably withheld. At the Indemnitor's request and
expense, each Indemnitee shall, and shall cause its employees to, provide full
information and reasonable assistance to Indemnitor and its legal
representatives with respect to the related Claim(s).
2.8 Notwithstanding anything herein seemingly to the contrary,
Customer shall have no indemnity obligations under this Clause 2 for any losses,
damages, liabilities, settlements, penalties, fines, costs and expenses to the
extent such losses, damages, liabilities, settlements, penalties, fines, costs
and expenses arise out of or result from:
2.8.1 ***; or
2.8.2 ***, or
2.8.3 ***; or
2.8.4 ***.
2.9 The provisions of this Clause 2, and the obligations of the
Customer and LB, respectively, under this Clause 2, shall survive the expiration
or termination for whatever reason of the Agreement.
2.10 CLAUSE 2.4 IS IN LIEU OF ALL OTHER CONDITIONS, WARRANTIES AND
STATEMENTS IN RESPECT OF THE CELL LINE, CUSTOMER MATERIALS, CUSTOMER
INFORMATION, CUSTOMER KNOW-HOW, CUSTOMER PATENT RIGHTS, CUSTOMER PROCESS, NEW
CUSTOMER INTELLECTUAL PROPERTY, AND CUSTOMER TECHNOLOGY, WHETHER EXPRESSED OR
IMPLIED BY STATUTE, CUSTOM OF THE TRADE OR OTHERWISE (INCLUDING WITHOUT
LIMITATION ANY SUCH CONDITION, WARRANTY OR STATEMENT RELATING TO THE DESCRIPTION
OR QUALITY OF THE CELL LINE, CUSTOMER MATERIALS, CUSTOMER INFORMATION, CUSTOMER
KNOW-HOW, CUSTOMER PATENT RIGHTS, CUSTOMER PROCESS, NEW CUSTOMER INTELLECTUAL
PROPERTY, AND CUSTOMER TECHNOLOGY, THEIR FITNESS OR SUITABILITY FOR A PARTICULAR
PURPOSE OR USE UNDER ANY CONDITIONS WHETHER OR NOT KNOWN TO CUSTOMER) AND ANY
SUCH CONDITION, WARRANTY OR STATEMENT IS HEREBY EXCLUDED.
3. PROVISION OF THE SERVICES
CONFIDENTIAL TREATMENT
12
3.1 LB shall diligently carry out the Services as provided in
Schedule 2, and shall use all reasonable efforts consistent with levels of
effort that LB uses with its most important customers, to achieve the objectives
and estimated timescales set out in that Schedule and deliver the Product,
samples of the Product, and other Deliverables to Customer as provided in
Schedule 2; provided, however, that the timescales and Product quantities set
forth in Schedule 2 are estimates only. LB shall communicate with Customer
regularly regarding LB's performance of the Services and shall inform Customer
promptly if LB determines that LB will not or may not be able to meet the
objectives or timescales, or deliver the Product quantities, Product samples, or
other Deliverables set forth in Schedule 2.
3.2 LB shall perform Runs and manufacture the Product in accordance
with this Agreement, and, except as expressly set forth to the contrary in
Schedule 2 or as otherwise agreed to by the parties from time to time, in
compliance with the Legal Requirements, including without limitation the
requirements of cGMP, LB warrants and covenants that, except as expressly set
forth to the contrary in Schedule 2 and in Clause 3.3 below, the Product
resulting from the Runs shall conform to the Specifications. The Product
resulting from the Runs shall be provided to Customer at no additional cost to
Customer over and above the Price, and Customer may make whatever further use of
such Product as Customer shall determine in its sole discretion, provided,
however, that, in accordance with Schedule 2, the Product manufactured in Stage
5 shall not be used in humans.
3.3 The parties agree that the *** Batches of Product manufactured
under Stage 8 of Schedule 2 attached hereto shall comply fully with cGMP and
with the parameters and target Specifications agreed to jointly by LB and the
Customer, with an emphasis on the safety of the Product for use in human
clinical testing and with pass/fail testing for analytical methods relating to
safety. In addition, notwithstanding anything in Schedule 3 seemingly to the
contrary, with respect to the Batches of Product manufactured under Stage 8,
Customer shall ***.
3.3.1 ***
If a failure to perform the Services or produce the Product for Delivery
arises due to a breach of this Agreement by LB, or LB's negligent act or
omission or willful misconduct, Customer shall be entitled to all of its rights
and remedies.
3.4 LB shall comply with cGMP and the International Committee for
Harmonisation ("ICH") regulatory requirements, from time to time and to the
extent that the foregoing are applicable to the Services. In the event of a
conflict between the ICH regulatory requirements and the cGMP regulatory
requirements, the cGMP regulatory requirements shall prevail, except as may
otherwise be agreed by the parties in writing.
3.5 LB hereby undertakes not to use the Cell Line, the Customer
Materials, the Customer Information, the Customer Technology, the Customer
Know-How or the Customer Patent Rights, or any part of any of the foregoing, for
any purpose other than to perform the Services and supply Product under this
Agreement. The obligations of LB under this Clause 3.6 shall survive the
expiration or termination for whatever reason of the Agreement.
CONFIDENTIAL TREATMENT
13
3.6 LB shall:
3.6.1 at all times use best efforts to keep the Cell Line, the
Customer Materials and the Product secure and safe from loss and damage;
3.6.2 not part with possession of the Cell Line or the
Customer Materials or the Product, except as permitted under Clause 3.8 below
for the purpose of tests at the Testing Laboratories.
3.7 LB shall procure that all Testing Laboratories are subject to
obligations of confidence and non-use substantially in the form of and at least
as strict as those obligations of confidence and non-use imposed on LB under
this Agreement. Each Testing Laboratory shall be subject to the prior written
approval of Customer, which approval shall not be unreasonably withheld.
Notwithstanding anything herein seemingly to the contrary, Customer shall have
the right, at Customer's option and with no penalty, to enter into an agreement
directly with one or more of the Testing Laboratories, and transfer the
associated testing services from LB under this Agreement to the Testing
Laboratory. LB shall ensure that Customer has the right to perform, directly or
through Customer's representatives, inspections and audits of all Testing
Laboratories, and Customer may condition Customer's approval of any Testing
Laboratory to Customer's performance of and satisfaction with the results of
such an inspection and audit. Customer shall perform and shall cause its
representatives to perform any such inspections and audits in compliance with
Clause 4 of this Agreement. Notwithstanding Customer's approval of any Testing
Laboratory, LB shall not disclose the contents of this Agreement (including
without limitation the Schedules hereto) or any of Customer's Confidential
Information to such approved Testing Laboratory except to the extent necessary
for such Testing Laboratory to conduct the related tests, and LB shall not
transfer possession of any of the Cell Line, Customer Materials or Product to
such approved Testing Laboratory except to the extent necessary for such Testing
Laboratory to conduct the related tests. Neither LB nor Customer shall be liable
in connection with this Agreement for any of the acts or omissions of the
Testing Laboratories. LB waives, releases and agrees not to assert against
Customer any claims for any losses, damages, liabilities, settlements,
penalties, fines, costs and expenses of any nature that LB may incur which
directly or indirectly arise out of or result from any negligent acts or
omissions or willful misconduct of the Testing Laboratories; ***. LB shall, at
Customer's expense, cooperate fully with Customer in the investigation and
prosecution of any claim, lawsuit or other proceeding by Customer against a
Testing Laboratory in connection with this Agreement for losses, damages,
liabilities, settlements, penalties, fines, costs and expenses of any nature
that Customer may incur which directly or indirectly arise out of or result from
any negligent acts or omissions or willful misconduct of the Testing
Laboratories, Nothing in this Clause shall release or shall be deemed to release
either party from any liability which arise out of or result from that party's
own negligent acts or omissions or willful misconduct. This Clause 3.8 shall
survive the expiration or termination for whatever reason of the Agreement.
3.8 LB shall procure, maintain and store such amounts of raw
materials and components as required for the Runs, and shall perform testing and
evaluation of such materials and components as set forth in the Quality
Agreement attached hereto as Schedule 4 or agreed upon in
CONFIDENTIAL TREATMENT
14
writing by the parties, and the cost and expense for such materials and
components and the testing and evaluation of such materials and components shall
be deemed included in the Prices shown on Schedule 3 hereto. LB shall be
responsible for and Customer may assist with oversight and coordination of the
supply logistics for the raw materials and components required for the Runs. LB
shall not procure Specialized Raw Materials (defined below) until authorized to
do so by Customer.
3.9 The term "Specialized Raw Materials" as used in this Agreement
means the specialized raw materials and components which are used under this
Agreement to manufacture the Product. The parties shall in good faith agree in
writing which raw materials and components shall be deemed to be "Specialized
Raw Materials" for the purposes of this Clause 3.10. In the event the cost and
expense of any Specialized Raw Materials materially exceed LB's original pricing
assumptions for such Specialized Raw Materials under this Agreement, then
Customer shall pay to LB the difference between the assumed cost and expense for
such Specialized Raw Materials and the actual cost and expense (not including
any LB xxxx-up or administrative fees) for such Specialized Raw Materials.
4. QUALITY; PROJECT MANAGEMENT
4.1 Responsibility for quality assurance and quality control shall
be allocated between the parties in accordance with the Quality Agreement, a
copy of which is attached hereto as Schedule 4, and standard operating
procedures as may be agreed upon in writing by the parties from time to time.
4.2 Customer and its designated representatives shall have the right
to witness, inspect and audit the performance of LB's obligations, at the times
and for durations set forth in the Quality Agreement and as otherwise agreed by
the parties. Customer shall have access to the facilities, data and records of
LB which are related to this Agreement for the purpose of conducting such
inspections and audits, and LB shall use reasonable endeavours to ensure that
all Testing Laboratories provide similar access to the Testing Laboratories'
facilities, data and records which are related to this Agreement for such
purposes. In accordance with the Quality Agreement, Customer shall have the
right to review LB's non-proprietary standard operating procedures relating to
the services of LB under the Quality Agreement or this Agreement.
4.3 In accordance with the Quality Agreement, Customer will have the
sole right to correspond with and submit regulatory applications and other
filings to the FDA, EMEA and other regulatory authorities to obtain approvals to
import, export, conduct clinical trials with, or take any other action with
respect to the Product, alone or with other products (collectively,
"Approvals"), when and as Customer may deem useful or necessary. Accordingly,
except as otherwise required by Legal Requirements, LB will not correspond
directly with the FDA, EMEA or any other regulatory agency with respect to the
Product without, in each instance, first obtaining Customer's prior written
consent. Notwithstanding the foregoing, LB will assist Customer, as requested by
Customer and at Customer's expense, in preparing, submitting, and maintaining
applications for such Approvals.
4.4 As set forth with particularity in the Quality Agreement, LB
will permit the FDA, EMEA and other regulatory authorities to conduct
inspections of LB's facilities as the FDA,
CONFIDENTIAL TREATMENT
15
EMEA or other regulatory authorities may request, and will cooperate with the
FDA, EMEA or other regulatory authorities with respect to the inspections and
any related matters, in each case related to the Product.
4.5 Notwithstanding anything in this Agreement seemingly to the
contrary, LB shall not undertake any modifications to the Process or testing
processes that could delay or otherwise impact the Approvals or other regulatory
submissions, including without limitation, regulatory product reviews,
Investigational New Drug applications (INDs), or any other compliance status
without in each case the prior written agreement of Customer.
4.6 In accordance with the Quality Agreement, Customer shall have
the right (a) to review the specifications, grades and vendors of all raw
materials and components used under this Agreement to manufacture the Product,
and (b) to approve the specifications, grades and vendors of all Critical Raw
Materials (defined below), including excipients, and of all raw materials and
components of animal or human origin, all to the extent used under this
Agreement to manufacture the Product. Customer shall provide a written list to
LB of those certain raw materials and components which shall constitute and be
deemed to be "Critical Raw Materials" for purposes of this Agreement, and shall
update the list from time to time as appropriate. Each version of the written
list of the Critical Raw Materials shall be jointly agreed to by Customer and
LB. Raw materials of and components of animal or human origin shall be avoided
when possible.
4.7 By not later than March 31, 2004, the Parties will establish a
Joint Project Team (the "JPT"). The JPT shall be composed of representatives
appointed by each of LB and the Customer. Such representatives may include, but
not be limited to, the Project Manager, Technical Lead, Manufacturing Lead,
Quality Control Lead, Quality Assurance/Regulatory Lead, Raw Materials Lead,
Supply Chain Lead and Engineering Lead, or other individuals with expertise and
responsibilities in the same areas of manufacturing, process sciences, quality
control or regulatory affairs. The JPT will meet by teleconference at least once
each week, or more frequently, as agreed by the JPT. The JPT will operate by
unanimous decision, except as expressly set forth herein. If the JPT is unable
to resolve a dispute regarding any issue presented to it, such dispute shall be
resolved in accordance with Clause 11.4. The JPT is responsible for the daily
monitoring and guidance of the Services to successfully achieve the deliverables
of the project as outlined herein.
4.8 By not later than March 31, 2004, each Party shall appoint a
Project Manager to act as the primary contact for such Party in connection with
matters related to the performance of the Services. Each such Project Manager,
unless otherwise mutually agreed, shall serve as a member of the JPT.
4.9 As set forth in the Quality Agreement, Customer shall have the
right to designate one of its employees or consultants as Customer's person on
plant, to be present in LB's facility during normal business hours during the
term of this Agreement to observe the Runs and observe LB's performance of its
obligations under this Agreement at times and for durations to be agreed. While
at LB's facility, Customer's representative shall comply with all of LB's
applicable policies and procedures, and, at LB's option, shall be escorted by LB
personnel.
CONFIDENTIAL TREATMENT
16
5. DELIVERY, TRANSPORTATION OF PRODUCT AND CUSTOMER TESTS
5.1 *** Unless otherwise agreed, LB shall package and label
Manufactured Product for Delivery in accordance with the Specifications and its
standard operating procedures and all applicable Legal Requirements. It shall be
the responsibility of the Customer to inform LB in writing in advance of any
special packaging and labeling requirements for Manufactured Product. All
additional costs and expenses of whatever nature incurred by LB in complying
with such special requirements shall be charged to the Customer in addition to
the Price, Transportation of Manufactured Product, whether or not under any
arrangements made by LB on behalf of Customer, shall be made at the sole risk
and expense of the Customer, provided that LB has complied with any instructions
provided by Customer with respect to transportation and insurance as set forth
in Clauses 5.2 and 5.3 below.
5.2 If requested in writing by the Customer, LB will (acting as
agent of the Customer for such purpose) arrange the transportation of
Manufactured Product from LB's premises to the third-party fill-finish
contractor or other destination indicated by the Customer, together with
insurance coverage for Manufactured Product in transit at its invoiced value.
All additional reasonable costs and expenses of whatever nature incurred by LB
in arranging such transportation and insurance shall be charged to the Customer
in addition to the Price provided that LB has obtained Customer's prior written
consent to incurring such additional costs and expenses.
5.3 If requested in writing by the Customer, LB will (acting as
agent for Customer) arrange for insurance of Product whilst held by LB after
Delivery (awaiting transportation). The costs and expenses of such insurance
shall be at Customer's expense and on reasonable terms equivalent to those under
which LB insures other comparable products prior to Delivery. All such
additional reasonable costs and expenses of whatever nature incurred by LB in
arranging such insurance shall be charged to the Customer in addition to the
Price, provided that LB has obtained Customer's prior written consent to
incurring such additional costs and expenses. Notwithstanding the foregoing, in
the event LB has been requested to arrange the transportation of Manufactured
Product in accordance with Clause 5.2 above, the costs and expenses of such
insurance of Manufactured Product whilst held by LB after Delivery (awaiting
transportation) shall be at LB's expense for up to fourteen (14) days and
thereafter shall be at Customer's expense, provided, however, that in the event
the delay in transportation is caused by LB, then the costs and expenses of such
insurance shall be at LB's expense until the Manufactured Product has been
loaded onto the appropriate collecting vehicle, except as may be otherwise
agreed by the parties in writing.
5.4 LB shall deliver to Customer the Certificate of Analysis not
later than the date of Delivery. Notwithstanding the foregoing, at Customer's
request, LB will Deliver Manufactured Product in quarantine prior to delivery of
the Certificate of Analysis. Such request shall be accompanied by Customer's
written acknowledgement that the Manufactured Product has been Delivered without
the transmittal to Customer of a Certificate of Analysis, that accordingly the
Manufactured Product cannot be administered to humans until transmittal of the
Certificate of Analysis, and that Customer nevertheless accepts full risk of
loss to and title and ownership of the Manufactured Product. The Delivery of
Product in quarantine shall be subject to such testing
CONFIDENTIAL TREATMENT
17
requirements as LB may reasonably require, and the *** period referred to in
Clause 5.7 shall run from Customer's receipt of samples of such Manufactured
Product together with the related consolidated Batch record.
5.5 Where LB has made arrangements for the transportation of
Manufactured Product, the Customer shall diligently examine the Manufactured
Product as soon as practicable after receipt. Notice of all claims (time being
of the essence) arising out of:
5.5.1 visible damage to or total or partial loss of
Manufactured Product in transit shall be given in writing to LB within *** of
receipt by Customer at Customer's facility or of receipt by Customer's third
party supplier at such third party's facility; or
5.5.2 non-Delivery shall be given in writing to LB within ***
after the later of (a) the date of LB's despatch notice, and (b) Customer's
actual knowledge of non-Delivery.
5.6 The Customer shall make damaged Manufactured Product and
associated packaging materials available for inspection and shall comply with
the requirements of any insurance policy covering the Manufactured Product of
which LB has given Customer notice. LB shall offer the Customer all reasonable
assistance (at the cost and expense of the Customer) in pursuing any claims
arising out of the transportation of Manufactured Product.
5.7 LB shall deliver to Customer samples of all Batches manufactured
under this Agreement, as and when Batches are manufactured, together with the
related consolidated Batch record requested by Customer to enable Customer to
inspect and perform testing on such samples. Promptly following receipt of
Manufactured Product or any sample thereof, the Customer may inspect the
Manufactured Product or sample and carry out any of the tests outlined or
referred to in the Specifications set out in Schedule 1 and such additional
tests as may be prudent in Customer's reasonable discretion. Subject to Clause
3.2, if such tests show that the Manufactured Product fails to meet the
Specifications, the Customer shall give LB written notice thereof within ***
after Customer's receipt at Customer's facility of samples of such Batch
together with the related consolidated Batch record and shall return such
Manufactured Product (except for reference samples retained by Customer) at LB's
expense to LB's premises for further testing. In the absence of such written
notice, Manufactured Product shall be deemed to have been accepted by the
Customer as meeting the Specifications. Subject to Clause 3.2, if Customer has
reasonably demonstrated to LB that Manufactured Product returned to LB fails to
meet the Specifications, and LB has failed to prove that such failure is due (in
whole or in part) to acts or omissions of the Customer or any third party after
Delivery, LB shall at Customer's discretion refund that part of the Price that
relates to the production of such Manufactured Product or replace such
Manufactured Product at LB's own cost and expense. In the event Customer
requires LB to replace such Manufactured Product, LB shall use all reasonable
endeavours to do so as soon as possible with the minimum delay.
5.8 Subject to Clause 3.2, if there is any dispute concerning
whether Manufactured Product returned to LB fails to meet the Specifications or
whether such failure is due (in whole or in part) to acts or omissions of the
Customer or any third party after Delivery, such
CONFIDENTIAL TREATMENT
18
dispute shall be resolved in accordance with the dispute resolution procedures
described in Clause 11.4 below.
5.9 Subject to Clause 7, LB's liability hereunder in respect of
Manufactured Product that fails to meet the Specifications shall be limited to
refund or replacement, in accordance with and as set forth with more
particularity in Clause 5,7 above; provided, however, that the foregoing
limitation of liability shall not apply in the event such failure is caused by
the negligent act or omission or willful misconduct of LB.
6. PRICE AND TERMS OF PAYMENT
6.1 Unless otherwise indicated in writing by LB, all prices and
charges payable to Lonza are exclusive of Value Added Tax or of any other
applicable taxes, levies, imposts, duties and fees of whatever nature imposed by
or under the authority of any government or public authority, which shall be
paid by the Customer (other than taxes on LB's income). LB shall add all such
taxes as separate line items on invoices. All invoices are strictly net and
payment must be made within thirty (30) days of Customer's receipt of invoice.
Notwithstanding the foregoing, no amounts shall be invoiced until such amounts
are then due and payable in accordance with the Schedules to this Agreement,
including without limitation and as appropriate the completion of the related
Services and Customer's receipt and acceptance of the related Deliverables. The
invoices shall be in ***, and all payments made by Customer shall be made in
***.
6.2 In default of payment on due date:
6.2.1 interest shall accrue on any amount overdue at the per
annum interest rate *** above *** from time to time as published in the "Money
Rates" section of The Wall Street Journal, on the 1st business day of each
month, beginning with the month in which the payment became delinquent, with
interest to accrue on a day to day basis both before and after judgement, adjust
monthly on the 1st day of each month, beginning with the second month of
delinquency, and be calculated on the number of days such payment is delinquent;
and
6.2.2 For so long as such payment delinquency remains uncured,
LB shall, at its sole discretion, and without prejudice to any other of its
accrued rights, be entitled to suspend the provision of the Services or, if
Customer has not remedied such payment delinquency within *** of the receipt by
Customer of notice of nonpayment and demand for remedy, to treat the Agreement
as repudiated.
7. LB WARRANTIES AND COVENANTS AND INDEMNITY
7.1 LB warrants and covenants that:
7.1.1 the Services shall be performed in accordance with this
Agreement, including without limitation Clauses 3.1 and 3.2 above;
CONFIDENTIAL TREATMENT
19
7.1.2 LB has the right and necessary corporate authorisations
to enter into this Agreement;
7.1.3 LB has the necessary rights to licence or permit
Customer to use the LB Process, LB Know-How, LB Patent Rights, and New General
Application Intellectual Property in accordance with the terms of this
Agreement, including without limitation in accordance with and pursuant to
Clause 9 below;
7.1.4 any of the LB Process, LB Know-How, LB Patent Rights,
and New General Application Intellectual Property referred to in Clause 7.1.3
above that are not owned by LB are licensed to LB under a licence which grants
LB the necessary rights to licence or permit Customer to use the LB Process, LB
Know-How, LB Patent Rights, and New General Application Intellectual Property in
accordance with the terms of this Agreement, including without limitation in
accordance with and pursuant to Clause 9 below;
7.1.5 LB will not cause or permit any liens or encumbrances of
any kind arising through LB to attach to Product, and unencumbered title to
Manufactured Product will be conveyed to Customer upon Delivery;
7.1.6 the LB Know How, LB Patent Rights, LB Process and the
New General Application Intellectual Property are owned by LB or LB is otherwise
entitled to use them for the purposes of providing Services under this Agreement
and LB shall not do or cause anything to be done which would adversely affect
their ownership or entitlement to use the same for those purposes;
7.1.7 to the best of LB's knowledge and belief, the use of the
LB Process, LB Know-How, LB Patent Rights, and New General Application
Intellectual Property in accordance with the terms of this Agreement (including
without limitation the use by Customer in accordance with and pursuant to the
provisions of Clause 9 below) do not and will not infringe any intellectual
property rights or industrial property rights of any third party (including
without limitation any LB Affiliate) and do not involve the wrongful use of any
trade secret or confidential information, nor is there any claim to the contrary
outstanding;
7.1.8 LB will notify Customer in writing immediately if it
receives or is notified of a claim that the use by LB of the LB Process, LB
Know-How, LB Patent Rights and/or New General Application Intellectual Property
for Services or the use by Customer in accordance with the terms of this
Agreement infringes any third party's intellectual property rights or industrial
property rights or involves the wrongful use of any trade secret or confidential
information; and
7.1.9 at the date of this Agreement LB is not a party to any
agreement that prohibits or prevents it from performing the Services or
otherwise fulfilling its obligations under this Agreement and covenants that it
will not enter into any such agreement.
7.2 CLAUSES 3, 4 AND 7.1 ARE IN LIEU OF ALL CONDITIONS, WARRANTIES
AND STATEMENTS IN RESPECT OF THE SERVICES AND/OR THE
CONFIDENTIAL TREATMENT
20
PRODUCT WHETHER EXPRESSED OR IMPLIED BY STATUTE, CUSTOM OF THE TRADE OR
OTHERWISE (INCLUDING BUT WITHOUT LIMITATION ANY SUCH CONDITION, WARRANTY OR
STATEMENT RELATING TO THE DESCRIPTION OR QUALITY OF THE PRODUCT, ITS FITNESS OR
SUITABILITY FOR A PARTICULAR PURPOSE OR USE UNDER ANY CONDITIONS WHETHER OR NOT
KNOWN TO LB) AND ANY SUCH CONDITION, WARRANTY OR STATEMENT IS HEREBY EXCLUDED.
7.3 Subject to and except to the extent of any indemnification from
Customer pursuant to Clauses 2.5 and 2.6 above, LB undertakes to indemnify and
to maintain Customer promptly indemnified against all losses, damages,
liabilities, settlements, penalties, fines, costs and expenses of any nature
(including court costs and reasonable legal fees on a full indemnity basis),
that Customer may incur to the extent such liabilities arise directly out of or
result from any claim, lawsuit or other action by a third party arising out of
or resulting from (a) any breach of any of the warranties given by LB in Clause
7.1 above; or (b) any negligent act or omission or willful misconduct of LB.
7.4 Notwithstanding anything herein seemingly to the contrary, LB
shall have no indemnity obligations under this Clause 7 for any losses, damages,
liabilities, settlements, penalties, fines, costs or expenses to the extent such
losses, damages, liabilities, settlements, penalties, fines, costs and expenses
arise out of or result from: ***
7.5 Nothing contained in this Agreement shall purport to exclude or
restrict any liability for death or personal injury resulting directly from
negligence by LB in carrying out the Services or any liability for breach of the
implied undertakings of LB as to title.
7.6 This Clause 7 and the obligations of LB under this Clause 7
shall survive the expiration or termination for whatever reason of the
Agreement.
8. CONFIDENTIALITY AND NON-USE
8.1 The Customer acknowledges that LB Know-How, LB Process, LB
Patent Rights and General Application Intellectual Property and any of LB's
other Intellectual Properly disclosed to, supplied to or held by Customer
pursuant to this Agreement, and LB acknowledges that Customer Know-How, Customer
Patent Rights, Customer Technology, Customer Information, Customer Process, New
Customer Intellectual Property, Customer Materials and the Cell Line and any of
Customer's other Intellectual Property disclosed to, supplied to or held by LB
pursuant to this Agreement (all of the foregoing collectively referred to as
"Confidential Information") is, subject to Clause 8.5, supplied and shall be
held in circumstances imparting an obligation of confidence and each agrees to
keep the other party's Confidential Information secret and confidential and to
respect the other's proprietary rights therein and not at any time for any
reason whatsoever to disclose or permit such Confidential Information to be
disclosed to any third party save as expressly provided herein or to be used for
any purpose not expressly authorized under this Agreement For the avoidance of
doubt, the parties agree that all portions of documents and records describing
and to the extent relating to the Product and the Customer Process shall be kept
confidential by Lonza in accordance with the terms of this Clause 8.
CONFIDENTIAL TREATMENT
21
8.2 The Customer and LB shall each procure that all their respective
employees, consultants, contractors and persons for whom it is responsible
having access to the other party's Confidential Information shall be subject to
the same obligations of confidence as the principals pursuant to Clauses 8.1 and
8.3 and, in addition, with respect to LB, to the same obligations of non-use
pursuant to Clauses 2.3, 3.6 and 8.1, and shall be bound, by written
confidentiality agreements in support of all such obligations.
8.3 LB and the Customer each undertake, except as set forth herein,
not to disclose or permit to be disclosed to any third party, or otherwise make
use of or permit to be made use of (a) any Confidential Information of the
other, or of any Affiliate of the other, or of any suppliers, agents,
distributors, licensees or other customers of the other which comes into the
receiving party's possession under this Agreement or (b) the commercial terms of
this Agreement, except to the extent that any of the foregoing is required to be
disclosed pursuant to subpoena, court order, judicial process or otherwise by
law, provided the receiving party provides prompt notice to the disclosing party
of such requirement in order to give the disclosing party an opportunity to
timely seek a protective order or other appropriate judicial relief. In the
event the disclosing party is unable to obtain a protective order or other
appropriate judicial relief, the receiving party shall disclose only that
portion of the disclosing party's Confidential Information which is legally
required to be disclosed, and ensure that all such Confidential Information of
the disclosing party shall be redacted to the fullest extent permitted by law
prior to such disclosure and that the disclosing party shall be given an
opportunity to review the Confidential Information prior to its disclosure.
Notwithstanding the foregoing, (i) LB may disclose Customer's Confidential
Information to LB's Affiliate, Lonza Biologics, Inc., for purposes consistent
with this Agreement; provided, however, that LB shall ensure that its Affiliate
is subject to obligations of confidentiality and non-use with respect to the
Confidential Information at least as strict as those set forth herein, and
provided further that LB shall remain liable for the acts or omissions of its
Affiliate with respect to such Confidential Information, and (ii) either party
may disclose the other party's Confidential Information to any contractors or
consultants approved in writing by the other party, such approval not to be
unreasonably withheld or delayed, for purposes consistent with this Agreement;
provided, however, that in each case the party disclosing the other party's
Confidential Information shall ensure that the third party receiving the
information is subject to contractual obligations of confidentiality and non-use
with respect to the Confidential Information at least as strict as those set
forth herein; and provided further that the party disclosing the other party's
Confidential Information shall remain liable for the acts or omissions of such
third party with respect to such Confidential Information.
8.4 The obligations of confidence referred to in this Clause 8 shall
not extend to any information which:
8.4.1 is or becomes generally available to the public
otherwise than by reason of a breach by the recipient party of the provisions of
this Clause 8;
8.4.2 is known to the recipient party and is at its free
disposal, without an obligation of confidence, prior to its receipt from the
disclosing party;
CONFIDENTIAL TREATMENT
22
8.4.3 is subsequently disclosed to the recipient party without
being made subject to an obligation of confidence; or
8.4.4 is developed by any servant or agent of the recipient
party without access to or use or knowledge of the Confidential Information of
the disclosing party.
8.5 The parties acknowledge that:
8.5.1 without prejudice to any other rights and remedies that
the parties may have, the parties agree that the Confidential Information is
valuable and that damages may not be an adequate remedy for any breach of the
provisions of Clauses 2.3, 3.6, 8.1, 8.2, 8.3 and 8.4. The parties agree that
the relevant party will be entitled without proof of special damage to the
remedies of an injunction and other equitable relief for any actual or
threatened breach by the other party;
8.5.2 Customer acknowledges that, save as expressly provided
in this Agreement (including without limitation Clauses 9.8.4 and 9.8.7 below),
the Customer shall not at any time have any right, title, license or interest in
or to LB Know-How, the LB Patent Rights, the LB Process, the New General
Application Intellectual Property or any of LB's other Intellectual Property,
and
8.5.3 LB acknowledges that, save as expressly provided in this
Agreement, LB shall not at any time have any right, title, license or interest
in or to the Customer Information, the Customer Materials, the Cell Line,
Customer Know-How, Customer Patent Rights, the Customer Technology, the New
Customer Intellectual Property, the Customer Process or any of Customer's other
Intellectual Property.
8.6 This Clause 8 and the obligations of LB and the Customer under
this Clause 8 shall survive the expiration or termination for whatever reason of
the Agreement.
9. TERMINATION; OWNERSHIP; LICENSE RIGHTS
9.1 This Agreement shall begin on the Effective Date and, unless
earlier terminated as set forth in this Clause 9, shall terminate and expire
when the last obligation to be performed under this Agreement has been
performed. If it becomes apparent to either LB or the Customer at any stage in
the provision of the Services that it will not be possible to complete the
Services for scientific or technical reasons, and such party gives written
notice thereof to the other party, a sixty (60) day period shall be allowed for
good faith discussion and attempts to resolve such problems. If such problems
are not resolved within such period, LB and the Customer shall each have the
right to terminate the Agreement forthwith by notice in writing. In the event of
such termination, the Customer shall pay to LB a termination sum calculated by
reference to all the Services performed by LB prior to such termination
(including a pro rata proportion of the Price for any stage of the Services
which is in process at the date of termination) and all expenses reasonably
incurred by LB in giving effect to such termination, including the costs of
terminating any commitments entered into under the Agreement, such termination
sum not to exceed the Price.
CONFIDENTIAL TREATMENT
23
9.2 Customer may in its sole discretion terminate the Services at
any time for any reason or for no reason whatsoever by giving not less than ***
notice in writing to LB. In the event of termination pursuant to this Clause 9.2
and subject to Clauses 9.4 and 9.5, the Customer shall pay LB a termination sum
calculated in accordance with the principles of Clause 9.1 above plus;
9.2.1 in the event notice to terminate Services pursuant to
this Clause 9.2 is issued to LB six (6) months or less before LB's then
estimated start date for any stage of those Services which include cGMP
fermentation activities, Customer shall pay LB a sum equal to the full Price of
that stage or those stages in question, which payment shall fall due to LB on or
before the date of termination of such Services; or
9.2.2 in the event notice to terminate Services pursuant to
this Clause 9.2 is issued to LB more than six (6) but not more than twelve (12)
months before LB's then estimated start date for any stage of those Services
which include cGMP fermentation activities, Customer shall pay LB a sum equal to
eight-five percent (85%) of the full Price of that stage or those stages in
question, which payment shall fall due to LB on or before the date of
termination of such Services; or
9.2.3 in the event notice to terminate Services pursuant to
this Clause 9.2 is issued to LB more than *** before LB's then estimated start
date for any stage of Services which include cGMP fermentation activities, no
payment shall be due for the stage or stages in question.
9.3 The obligation to make payment under Clause 9.2 shall be reduced
(retrospectively, and hence LB shall make an appropriate refund to Customer) to
the extent that LB mitigates its loss in this regard (and LB shall promptly
notify the Customer of any such mitigation). LB shall make all reasonable
efforts so to mitigate such losses. This provision shall not entitle the
Customer to be refunded an amount greater than that paid by Customer to LB
pursuant to this Clause 9 ***.
9.4 For the avoidance of doubt, activities relating to cGMP
fermentation shall be deemed to commence with the date of removal of the vial of
cells for the performance of the fermentation from frozen storage.
9.5 In addition to the termination rights set forth above, the
parties may each terminate the Agreement forthwith by notice in writing to the
other party upon the occurrence of any of the following events:
9.5.1 if one party commits a material breach of the Agreement
(which shall include without limitation a breach of the warranties set out in
Clauses 2 and 7 respectively), and such breach is not capable of remedy, then
the non-breaching party may terminate the Agreement forthwith by notice in
writing to the breaching party, and, if such breach is capable of remedy but is
not remedied within *** of the receipt by the breaching party of notice
identifying the breach and requiring its remedy, then the non-breaching party
may terminate the Agreement forthwith by notice in writing to the breaching
party; or
CONFIDENTIAL TREATMENT
24
9.5.2 if one party ceases for any reason to carry on business
or compounds with or convenes a meeting of its creditors or has a receiver or
manager appointed in respect of all or any part of its assets or is the subject
of an application for an administration order or of any proposal for a voluntary
arrangement or enters into liquidation (whether compulsorily or voluntarily) or
undergoes any analogous act or proceedings under foreign law, then the other
party may terminate the Agreement forthwith by notice in writing to the
breaching party.
9.6 Upon the termination or expiration of the Agreement for whatever
reason:
9.6.1 LB shall cease all use of and shall promptly return to
the Customer all Customer Information and shall, as directed by Customer,
dispose of or return to the Customer the Customer Materials, the Cell Line, the
Product, the Deliverables, the Documentation, any in-process Product or
materials, and any materials deriving from any of the foregoing. Notwithstanding
the foregoing, the parties agree that, in the event LB has terminated the
Agreement pursuant to Clause 9.5.1 above because of a material payment default
by Trubion, men LB shall have no obligation to deliver Manufactured Product (or
Product to the extent the term "Product" refers to the tangible forms of the
Product manufactured under this Agreement using the Process) to Trubion as
required under this Clause 9.6.1 unless and until the payment default has been
cured;
9.6.2 LB shall not thereafter use or exploit the Customer
Know-How, Customer Patent Rights, the Customer Technology, the New Customer
Intellectual Property (including without limitation the Customer Process), the
Customer Information, the Cell Line, the Product, or the Customer Materials, or
any of Customer's other Intellectual Property;
9.6.3 the Customer shall promptly return to LB all LB Know-How
it has received from LB;
9.6.4 the Customer shall not thereafter use or exploit the LB
Patent Rights the LB Process or the LB Know-How or any of LB's other
Intellectual Property in any way whatsoever, except as permitted under and in
accordance with Clauses 9.8.4, 9.8.7, and 9.9 below and subject to the
provisions set forth in Clause 9.10 below;
9.6.5 LB shall refund within thirty (30) days of the effective
date of such termination all amounts paid to LB in excess of the amounts owed to
LB under this Agreement, including without limitation the amounts owed to LB if
any, pursuant to this Clause 9; and
9.6.6 LB and the Customer shall do all such acts and things
and shall sign and execute all such deeds and documents as the other may
reasonably require to evidence compliance with this Clause 9.6.
9.7 Expiration or termination of the Agreement for whatever reason
shall not affect the accrued rights of either LB or the Customer arising under
or out of this Agreement and all provisions which are expressed to survive the
Agreement shall remain in full force and effect. For the avoidance of doubt, the
provisions of Clauses 2, 3, 7, 8, 9, 11 and 14 will survive the expiration or
termination of this Agreement for any reason, and, except as otherwise expressly
provided in this
CONFIDENTIAL TREATMENT
25
Clause 9.7, all other rights and obligations of the parties under this Agreement
will terminate upon termination or expiration of this Agreement.
9.8 Ownership; License Rights.
9.8.1 Except as expressly provided in Clause 2.3 above and
Clause 9.8.7 below, neither party will, as a result of this Agreement, acquire
any right, title, or interest in any Intellectual Property that the other party
owned or controlled as of the Effective Date of this Agreement, or that the
other party obtains ownership or control of separate and apart from the
performance of this Agreement.
9.8.2 Except as expressly provided in Clause 9.8.4 below, LB
shall own all right, title and interest in "New General Application Intellectual
Property." which as used in this Agreement means Intellectual Property that LB
and/or its Affiliates, contractors or agents develops, conceives, invents,
reduces to practice or makes in the course of performance of this Agreement and
that meets each of the following three criteria: ***.
9.8.3 Except for and not including the New General Application
Intellectual Property, Customer shall own all right, title, and interest in any
and all Intellectual Property that LB and/or its Affiliates, the Testing
Laboratories or other contractors or agents of LB conceives, invents, reduces to
practice, develops or makes, solely or jointly with Customer or others, in the
course of performance of this Agreement or as a result of receipt of Customer
Technology (collectively, the "New Customer Intellectual Property"), including
without limitation the Customer Process and all improvements to the Customer
Technology. For the avoidance of doubt, the parties confirm that LB shall have
no obligation to cause any of the Testing Laboratories or other contractors or
agents of LB to assign their respective rights, titles and interests in any New
Customer Intellectual Property to Trubion, other than the obligations set forth
in Clause 9.8.5 below. LB hereby assigns to Customer and shall continue to
assign to Customer all of its right, title and interest in any New Customer
Intellectual Property. LB shall promptly disclose to Customer in writing all New
Customer Intellectual Property. LB shall execute, and shall require LB's
personnel involved in the performance of the Services to execute, any documents
required to confirm Customer's ownership of the New Customer Intellectual
Property, and any documents required to apply for, maintain and enforce any
patents or other rights in the New Customer Intellectual Property. Upon
Customer's request and at Customer's reasonable expense, and at no cost to LB,
LB shall assist Customer as may he necessary to apply for, maintain and enforce
any patents or other rights in the New Customer Intellectual Property. For the
avoidance of doubt, the parties agree that the term "New Customer Intellectual
Property" shall not under any circumstances be interpreted or defined to include
any "New General Application Intellectual Property."
9.8.4 Subject to Clause 9.10 below, LB hereby grants Customer
a non-exclusive, worldwide, fully paid-up, irrevocable and transferable license,
with the right to grant and authorize sublicenses, under and to all New General
Application Intellectual Property, to the extent such New General Application
Intellectual Property is useful or beneficial to develop, conduct
CONFIDENTIAL TREATMENT
26
clinical trials for, formulate, manufacture, test, seek regulatory approval for,
market, commercialize, make, have made, use, sell, import, and distribute
Product.
9.8.5 LB shall use its reasonable efforts to procure that all
Testing Laboratories and other contractors arid agents of LB involved in the
performance of the Services, and their respective personnel, shall be subject to
the same agreements and obligations as LB pursuant to Clauses 9.8.3 and 9.8.4,
and shall be bound by written agreements in support of all such agreements and
obligations, including without limitation an assignment to Customer all of the
Testing Laboratories, contractors and agents' right, title and interest in any
New Customer Intellectual Property.
9.8.6 Upon the earlier of the completion of the Services or
the termination or expiration of this Agreement, LB shall deliver to Customer
all materials related to the New Customer Intellectual Property, regardless of
the method of storage or retrieval, in such form as such materials are then
currently in the possession of LB. Alternatively, at Customer's written request,
LB shall dispose of such related materials or retain them for a period of time
agreed upon by the parties; provided, however, that Customer shall pay the
reasonable costs associated with LB disposing of or retaining such materials.
9.8.7 Subject to Clause 9.10 below, LB hereby grants Customer
a non-exclusive, worldwide, fully paid-up, irrevocable and transferable license,
with the right to grant and authorize sublicenses, under and to the LB Patent
Rights and LB Know-How to use the LB Patent Rights, the LB Know-How and the LB
Process, alone or in combination with the Customer Process or such other
technology or Intellectual Property that Customer chooses, in its sole
discretion, to develop, conduct clinical trials for, formulate, manufacture,
test, seek regulatory approval for, market, commercialize, make, have made, use,
sell, import, and distribute Product. For the avoidance of doubt, no licence is
granted to Customer under this Clause 9.8.7 or otherwise under this Agreement in
respect of LB's glutamine synthetase (GS) gene expression system, which shall be
the subject of a separate licence agreement between the parties.
9.9 The parties intend that the Process shall be fully portable by
Trubion. The parties intend that the Process shall be fully portable by Trubion.
At the request of Customer at any time and from time to time during the term of
this Agreement and within *** following the expiration or termination of this
Agreement, LB shall transfer to Customer (or its designee) the Process for the
Product and all manufacturing technology and know-how related thereto (the
"Technology Transfer"). ***.
9.10 Notwithstanding anything in Clause 9.8.4 or 9.8.7 seemingly to
the contrary, the parties agree as follows:
9.10.1 Upon the expiration or termination of this Agreement,
Customer shall have no right to exercise the license rights granted by LB to
Customer under Clauses 9.8.4 and 9.8.7 unless and until the Technology Transfer
fee has been paid in accordance with Clause 9.9 above.
CONFIDENTIAL TREATMENT
27
9.10.2 During the term of this Agreement, Customer shall have
no right to exercise the license rights granted by LB to Customer under Clauses
9.8.4 and 9.8.7 to manufacture the Product at a Trubion facility or at a
third-party facility that is not owned or operated by Lonza or its Affiliates,
unless and until the Technology Transfer fee described in Clause 9.9 above has
been paid.
Furthermore, for the avoidance of doubt, the parties agree that the Technology
Transfer shall be performed in accordance with and subject to the provisions of
Clause 9.9, and the parties acknowledge that Clause 9.9, and the obligations of
the parties thereunder, shall survive the expiration or termination of this
Agreement.
9.11 The terms of this Clause 9 shall survive the expiration or
termination for whatever reason of this Agreement.
10. FORCE MAJEURE
10.1 If either party is prevented or delayed in the performance of
any of its obligations under the Agreement by Force Majeure and shall give
written notice thereof to the other party specifying the matters constituting
Force Majeure together with such evidence as the party giving notice reasonably
can give and specifying the period for which it is estimated that such
prevention or delay will continue, the party giving notice shall be excused from
the performance or the punctual performance of such obligations as the case may
be from the date of such notice for so long as such cause of prevention or delay
shall continue. Notwithstanding the foregoing, in the event that LB is prevented
from performance by Force Majeure by longer than ***, Customer shall be entitled
to terminate this Agreement upon written notice, but such termination shall not
be considered as termination under Clause 9.5.1 hereof.
10.2 The expression "Force Majeure" shall be deemed to include any
cause affecting the performance by a party of the Agreement to the extent that
it arises from or attributable to acts, events, acts of God, omissions or
accidents beyond the reasonable control of the party giving notice of the Force
Majeure event.
11. GOVERNING LAW, JURISDICTION AND ENFORCEABILITY; DISPUTE RESOLUTION
11.1 The construction, validity and performance of the Agreement
shall be governed by the laws of ***. This Agreement shall not be governed by
the United Nations Convention on Contracts for the International Sale of Goods,
the application of which is disclaimed.
11.2 No failure or delay on the part of either LB or the Customer to
exercise or enforce any rights conferred on it by the Agreement shall be
construed or operate as a waiver thereof nor shall any single or partial
exercise of any right, power or privilege or further exercise thereof operate so
as to bar the exercise or enforcement thereof at any time or times thereafter.
CONFIDENTIAL TREATMENT
28
11.3 The illegality or invalidity of any provision (or any part
thereof) of this Agreement shall not affect the legality, validity or
enforceability of the remainder of its provisions or the other parts of such
provision as the ease may be.
11.4 If any dispute arises relating to the performance of either
party under this Agreement that the parties are unable to resolve in the
ordinary course of business (a "Dispute"), the parties will use good-faith
efforts to resolve the matter in accordance with this Clause 11.4 prior to
instituting any legal proceeding in connection therewith; provided, however,
that nothing herein will require either party to forego or delay the institution
of any proceeding to seek equitable or injunctive relief to stop or prevent any
breach of this Agreement if it reasonably believes that it would be irreparably
harmed by any delay in seeking such relief. If a dispute occurs, either party
may, by written notice to the other party, have such dispute referred to their
respective officers designated below (or their respective designees) for
attempted resolution by good faith negotiations within *** after such notice is
received. The original designated officers are:
For LB: Xxxx Xxxxxxxxxxxx, Director and Head of Slough Site
For Customer: Xx. Xxxxx X. Xxxxxxxx, MD, President and CEO.
In the event the designated officers (or their respective designees) are
not able to resolve such dispute within such ***, or such other period of time
as the parties may mutually agree in writing, the parties shall have the right
to pursue any and all remedies at law and in equity. Notwithstanding the
foregoing, Disputes regarding nonconforming bulk Product under Section 5.9 above
will be referred first to the officers designated above and then, in the event
that such officers are unable to resolve the Dispute, to an independent expert
(acting as an expert and not as an arbitrator) to be appointed by agreement
between LB and the Customer or, in the absence of agreement, by the President
for the time being of the Association of the British Pharmaceutical Industry.
The costs of such independent expert shall be borne equally between LB and the
Customer. The decision of such independent expert shall be in writing and, save
for manifest error on the face of the decision, shall be binding on both LB and
the Customer.
12. NOTICES
12.1 Any notice or other communication to be given under this
Agreement shall be delivered personally or sent by facsimile transmission and
acknowledged by the intended recipient, or if facsimile transmission is not
available, by first class pre-paid post addressed as follows:
If to Lonza Biologics to: Lonza Biologics plc
000 Xxxx Xxxx
Xxxxxx
Xxxxxxxxx XX0 0XX
Xxxxxxx
Facsimile: x00 0000 000000
For the attention of: ***
CONFIDENTIAL TREATMENT
29
If to the Customer to: Trubion Pharmaceuticals, Inc.
00000xx Xxx., Xxxxx 0000
Xxxxxxx, XX 00000
XXX
Facsimile: x0-000-000-0000
For the attention of: Xxxxxxx X. Xxxxxx, Ph.D.
Senior Vice President, R & D
or to such other destination as either party hereto may hereafter notify to the
other in accordance with the provisions of this Clause 12.
12.2 All such notices or other communications shall be deemed to
have been served as follows:
12.2.1 if delivered personally, at the time of such delivery;
12.2.2 if sent by facsimile, upon receipt of the transmission
confirmation slip showing completion of the transmission;
12.2.3 if sent by first class pre-paid post, upon receipt by
the addressee.
13. MISCELLANEOUS
13.1 Neither party shall be entitled to assign, transfer, charge or
in any way make over the benefit and/or the burden of this Agreement without the
prior written consent of the other which consent shall not be unreasonably
withheld or delayed, save that either party shall be entitled without the prior
written consent of the other to assign, transfer, charge, sub-contract, deal
with or in any other manner make over the benefit and/or burden of this
Agreement to an Affiliate or to any company with which the assigning party may
merge or to any company to which it may transfer its assets and undertakings.
13.2 The text of any press release or other communication to be
published by or in the media concerning the subject matter of the Agreement
shall require the prior written approval of LB and the Customer, LB shall not
make use of Customer's name in any advertisement or promotional material or
customer list without in each case the prior written consent of Customer.
Consent to be given under this Clause 13.2 shall not be unreasonably withheld or
delayed. Notwithstanding anything in this Agreement seemingly to the contrary,
LB hereby consents to Customer's disclosure of LB's name to Customer's current
and potential employees, directors, shareholders, investors, partners, and
subcontractors.
13.3 The Agreement embodies the entire understanding of LB and the
Customer and there are no promises, terms, conditions or obligations, oral or
written, expressed on implied, other than those contained in the Agreement, The
terms of the Agreement shall supersede all
CONFIDENTIAL TREATMENT
30
previous agreements (if any) which may exist or have existed between LB and the
Customer relating to the Services.
13.4 The parties to this Agreement do not intend that any term
hereof should be enforceable by virtue of the Contracts (Rights of Third
Parties) Xxx 0000 by any person who is not a party to this Agreement.
13.5 No variation of or addition to this Agreement or any part
thereof shall be effective unless in writing and signed on behalf of both
parties, Notwithstanding the above the parties hereby confirm that amendments to
the Specifications shall be effective if reduced to writing and signed by the
quality and/or regulatory representative of both parties, which quality and/or
regulatory representative shall be nominated from time to time by each party. In
the event of any conflict between the main body of this Agreement and any
Schedule, the terms of the main body of this Agreement shall control.
13.6 Each of the parties to this Agreement is an independent
contractor and nothing herein contained shall be deemed to constitute the
relationship of partners, joint venturers, nor of principal and agent between
the parties. Neither party shall hold itself out to third parties as purporting
to act on behalf of, or serving as the agent of, the other party.
13.7 This Agreement and any amendment hereto may be executed in any
number of counterparts, each of which shall be deemed an original and all of
which shall constitute the same instrument This Agreement may be executed by
facsimile or original, and a facsimile signature shall be deemed to be and shall
be as effective as an original signature.
14. LIMITATION OF LIABILITY; EXCLUSION OF CERTAIN DAMAGES
14.1 LB's aggregate liability for direct damages arising out of or
in connection with this Agreement or the transactions contemplated hereby shall
not exceed the total maximum aggregate sum payable under this Agreement for the
Services, in accordance with Schedule 3 (Price and Terms of Payment) attached
hereto, except that the foregoing limitation shall not apply in the case of (a)
breach of Clause 8 (Confidentiality and Non-Use) by LB, (b) personal injury or
death, or (c) grossly negligent or intentionally wrongful acts or omissions of
LB. The foregoing limitation shall also not apply to claims arising under, or
LB's breach of, Clause 7.1 within Clause 7 (LB Warranties and Covenants and
Indemnity); provided, however, that LB's aggregate liability for direct damages
arising out of or in connection with claims arising under, or LB's breach of,
Clause 7.1 within Clause 7 (LB Warranties and Covenants and Indemnity), shall
not exceed the greater of (a) the total maximum aggregate sum payable under this
Agreement for the Services, in accordance with Schedule 3 (Price and Terms of
Payment) attached hereto, and (b) ***.
14.2 NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY INCIDENTAL,
PUNITIVE, INDIRECT, OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING LOST
PROFITS, LOST DATA, LOST REVENUES, AND LOSS OF BUSINESS OPPORTUNITY, WHETHER OR
NOT THE OTHER PARTY WAS AWARE OR SHOULD HAVE BEEN AWARE OF THE POSSIBILITY OF
THESE DAMAGES, EXCEPT THAT THE
CONFIDENTIAL TREATMENT
31
FOREGOING LIMITATION SHALL NOT APPLY IN THE CASE OF (a) BREACH OF CLAUSE 8
(CONFIDENTIALITY AND NON-USE) BY EITHER PARTY, (b) PERSONAL INJURY OR DEATH, OR
(c) GROSSLY NEGLIGENT OR INTENTIONALLY WRONGFUL ACTS OR OMISSIONS. The terms of
this Clause 14 shall survive the expiration or termination for whatever reason
of this Agreement.
[The remainder of this page intentionally left blank]
CONFIDENTIAL TREATMENT
32
AS WITNESS the hands of the duly authorised representatives of the parties
hereto the day and year first above written.
Signed for and on behalf of Xxxx Xxxxxxxxxxxx
---------------------------------
LONZA BIOLOGICS PLC Senior Vice President
Head R & D Pharmaceuticals
---------------------------------
TITLE
Signed for and on behalf of /s/ Xxxxx X. Xxxxxxxx
---------------------------------
TRUBION PHARMACEUTICALS, INC.
President & CEO
---------------------------------
TITLE
CONFIDENTIAL TREATMENT
33
SCHEDULE 1
DEFINITIONS AND SPECIFICATIONS
DEFINITIONS
For the purpose of this document:
"Cell Line" shall mean the *** cell line created by the Customer expressing
Product.
"Product" shall mean the Small Modular ImmunoPharmaceutical (SMIP) produced by
the Cell Line known as TRU-015.
SPECIFICATIONS
1.1 EXAMPLE OF TYPICAL INITIAL SPECIFICATION FOR BULK PURIFIED PRODUCT
(These examples are only examples of typical specifications, and shall not
be considered to be the specifications related to the Product)
TEST METHOD SPECIFICATION
--------------- ------ -------------
CHARACTERISTICS
1.1.1 *** *** ***
1.1.2 *** *** ***
1.1.3 *** *** ***
1.1.4 *** *** ***
1.1.5 *** *** ***
1.1.6 *** *** ***
1.1.7 *** *** ***
1.1.8 *** *** ***
1.1.9 *** *** ***
1.1.10 *** *** ***
1.1.11 *** *** ***.
1.1.12 *** -*** ***-
1.2 EXAMPLE OF TYPICAL SPECIFICATION FOR BULK FERMENTER HARVEST
(These examples are only examples of typical specifications, and shall not
be considered to be the specifications related to the Product)
CONFIDENTIAL TREATMENT
1
TEST METHOD SPECIFICATIONS
---- ------ --------------
1.2.1 *** *** ***
1.2.2 *** *** ***
1.2.3 *** *** ***
CONFIDENTIAL TREATMENT
2
1.3 FINAL BULK PRODUCT DISPOSITION
1.3.1 Final Formulation Buffer: ***
1.3.2 Bottling of Bulk Product:
1.3.2.1 Containers ***
1.3.2.2 Denominations ***
***
1.3.3 Product Storage Conditions: ***
1.3.4 Shipment Temperature: ***
1.4 SPECIFICATION FOR CELL BANKS
STARTING MATERIAL DEFINITION
An *** of a cryopreserved *** will be created from the Cell Line provided
by the Customer and stored in individual ampoules in liquid nitrogen
refrigerators.
GENERAL *** SPECIFICATION
In order for the *** to be accepted into LB's cGMP facility, the following
testing is required and the appropriate specifications achieved.
TEST METHOD SPECIFICATIONS
---- ------ --------------
1.4.1 *** *** ***
***
*** *** ***
***
1.4.2 *** *** ***
1.4.3 *** *** ***
1.4.4 *** *** ***
1.4.5 *** *** ***
ONFIDENTIAL TREATMENTS
3
SCHEDULE 2
SERVICES
2. SERVICES
2.1 SUPPLY OF CUSTOMER MATERIALS AND CUSTOMER KNOW-HOW
Prior to commencement of the Services at LB or, if appropriate, prior to
the commencement of the relevant Stage of the Services, the Customer shall
supply LB with the following:
***
CONFIDENTIAL TREATMENT
1
2.2 ACTIVITIES TO BE UNDERTAKEN BY LB
***
CONFIDENTIAL TREATMENT
2
SCHEDULE 3
PRICE AND TERMS OF PAYMENT
1.0 PRICE
In consideration for LB carrying out the Services as detailed in Schedule
2, the Customer shall pay LB as follows:
***
CONFIDENTIAL TREATMENT
3
SCHEDULE 3
PRICE AND TERMS OF PAYMENT
2.0 PAYMENT
Payment by the Customer of the Price for each Stage shall be made against
LB's Invoices that will be issued as follows:
2.1 FOR STAGE 1
*** upon commencement of Stage 1.
*** upon issue of the deliverables for Stage 1 to the Customer.
2.2 FOR STAGE 2
*** upon commencement of Stage 2.
*** upon issue of the deliverables for Stage 2 to the Customer.
2.3 FOR STAGE 3
*** upon commencement of Stage 3.
*** upon issue of the deliverables for Stage 3 to the Customer.
2.4 FOR STAGE 4
*** upon commencement of Stage 4.
*** upon issue of the deliverables for Stage 4 to the Customer.
2.5 FOR STAGE 5
*** upon commencement of Stage 5.
*** upon issue of the deliverables for Stage 5 to the Customer.
2.6 FOR STAGE 6
*** upon commencement of Stage 6.
*** upon issue of the deliverables for Stage 6 to the Customer.
2.7 FOR STAGE 7
*** upon commencement of Stage 7.
*** upon issue of the deliverables for Stage 7 to the Customer.
2.8 FOR STAGE 8
*** upon ampoule thaw of each batch manufactured under Stage 8.
*** upon issue of the certificate of analysis for each batch
manufactured under Stage 8.
2.9 FOR STAGE 9
*** upon commencement of Stage 9.
*** upon issue of the deliverables for Stage 9 to the Customer.
2.10 FOR STAGE 10
100% upon issue of each timepoint interim report and upon issue
of the final report.
2.11 FOR STAGE 11
*** upon commencement of Stage 11.
*** upon issue of the deliverables for Stage 11 to the Customer.
2.12 FOR STAGE 12
CONFIDENTIAL TREATMENT
4
`
*** upon commencement of Stage 12.
*** upon issue of the deliverables for Stage 12 to the Customer.
2.13 FOR STAGE 13
*** upon commencement of Stage 13.
*** upon issue of the deliverables for Stage 13 to the Customer.
2.14 FOR STAGE 14
100% upon issue of each timepoint interim report and upon issue
of the final report.
CONFIDENTIAL TREATMENT
5
SCHEDULE 4
QUALITY AGREEMENT
[The remainder of this page intentionally left blank]
CONFIDENTIAL TREATMENT
6
QUALITY AGREEMENT
This quality agreement ("Quality Agreement") is dated effective as of 8th
January 2004, and it defines the roles and responsibilities for the quality
operations between LONZA BIOLOGICS PLC, the registered office of which is at 000
Xxxx Xxxx, Xxxxxx, Xxxxxxxxx XX0 0XX, Xxxxxxx (herein after referred to as
"LB"), and TRUBION PHARMACEUTICALS, INC., (formerly known as GENECRAFT, INC.) of
0000 0xx Xxxxxx, Xxxxx 0000, Xxxxxxx, XX 00000, XXX (herein after referred to as
the "Customer") with respect to manufacture of Customer's proprietary Small
Modular ImmunoPharmaceutical (SMIP) known as TRU-015 ("TRU-015") under that
certain development and manufacturing services agreement between the parties of
even date herewith (the "Services Agreement") in preparation for regulatory
filings and for human clinical use. When used in this Quality Agreement, the
term "Product" refers to TRU-015 and/or to the form of TRU-015 manufactured
under the Services Agreement, as the context requires.
This Quality Agreement takes the form of a detailed list of activities
associated with the manufacture, testing and release of Product. Responsibility
for each activity is assigned to either the Customer or LB, or is assigned to
both the Customer and LB, and additional details are provided in the Services
Agreement and in the SOP's referred to in this Quality Agreement.
This is the Quality Agreement that is referred to in the Services
Agreement. Capitalized terms used but not defined in this Quality Agreement
shall have the meaning given in the Services Agreement. This Quality Agreement
may be amended by written agreement of the parties. In the event of a conflict
between the Quality Agreement and the Services Agreement, the Services Agreement
shall control. This Quality Agreement may be executed in any number of
counterparts, each of which shall for all purposes be deemed an original and all
of which, taken together, shall constitute one and the same instrument. A
facsimile signature shall be deemed to be and shall be as effective as an
original signature.
The responsibilities and rights of the parties under this Quality
Agreement are set forth below:
a. OVERALL RESPONSIBILITIES
This Quality Agreement outlines the responsibilities of the Customer and
LB with respect to the quality assurance of Product manufactured and supplied by
LB for the Customer under the terms of the Agreement.
This Quality Agreement takes the form of a detailed list of activities
associated with the manufacture, testing and release of Product. Responsibility
for each activity is assigned to either the Customer or LB, or is assigned to
both the Customer and LB.
This detailed list describes generic quality activities that would be
performed by both parties for Product used in clinical trail supply. The
specific services to be provided by LB will be set out in
CONFIDENTIAL TREATMENT
1
the Agreement (and any Amendments to the Agreement) on Price and other terms
acceptable to both parties.
LB is responsible for ensuring that the quality requirements for Product
are as specified in the approved Product specification and that Product is
manufactured, tested and stored in accordance with current Good Manufacturing
Practices (cGMP) and all applicable US and EU regulations and ICH guidelines.
The Customer is responsible for shipping and the final review, approval,
and release of product for use in the clinic. The Customer is responsible for
Product development, technical oversight, product specifications and regulatory
agency filings.
b. SPECIFIC RESPONSIBILITIES
ITEM RESPONSIBILITIES AND RIGHTS
------------------------------------------ ----------------------------------------------------------------------------------
LB CUSTOMER(1)
---------------------------------------- -------------------------------------
1.0 Organisation and Personnel - Ensure adequate number of personnel - Right to audit
with appropriate training, skills,
knowledge and experience to
manufacture and test Product in and
Equipment utilities, equipment,
computerised systems and software are
properly designed, validated and
maintained in accordance with cGMP
2.0 Facilities, Utilities and Equipment - Ensure facilities, environment, - Right to audit
utilities, equipment, computerised
systems and software are properly
designed, validated and maintained in
accordance with cGMP
- Ensure Product is manufactured and - Right to audit
tested only at sites as agreed with
Customer
- Provide Customer with Drug Master - Include Drug Master File reference
File reference that will allow US FDA into regulatory submissions, as
the ability to cross-reference other appropriate
products that are manufactured at
LB's manufacturing and testing
locations
----------
(1) Throughout the Quality Agreement, Customer's column includes the phrase
"right to audit" - the use of this phrase in certain instances but not in
others does not and shall not imply that Customer's audit rights pursuant
to Clause 15 below are limited to those boxes where "right to audit"
appears.
CONFIDENTIAL TREATMENT
2
ITEM RESPONSIBILITIES AND RIGHTS
------------------------------------------ -------------------------------------------------------------------------------------
LB CUSTOMER(1)
---------------------------------------- ----------------------------------------
- Provide Customer with documentation
that no penicillin is manufactured or
tested at site
3.0 Raw Materials for Process and - Source, test and release raw - Right to audit; right to review all
Packaging of Product/Vendor materials and primary packaging of raw material specifications, grades
Qualification Process appropriate quality for processing of and vendors used in manufacture of
Product Product
- Customer to provide LB with list of
critical raw materials used in
Customer process; update with changes
as necessary
- Propose and jointly agree - Right to approve vendor, grade and
specifications, vendors and grade of specifications of critical raw
critical raw materials used in materials used in Customer process,
Customer process in accordance with including excipients, and raw
LB policy, with preference for materials of animal or human origin
non-animal and non-human derived raw
materials
- Acknowledge and support Customer's
goal not to use any raw materials of
animal or human origin in the
development of Customer process
- Retain representative samples - Right to audit
4.0 Cell Banks - Prepare, characterise and store cell -
bank(s) if requested by Customer
- Jointly agree on testing - Jointly agree on testing
specifications and test methods to specifications and test methods to
enable release of cell banks for use enable Product manufactured from cell
in LB's multi-product manufacturing banks to be used in the clinic
facility
- Perform stability testing of cell - Right to audit
bank(s) if requested by Customer and
share data with Customer
IF CELL BANK SUPPLIED BY CUSTOMER
- Review and approve characterisation - Supply cell bank characterisation
data. Store working stock or cell data for review and approval.
bank Transfer cell bank (or portion
thereof) to LB
CONFIDENTIAL TREATMENT
3
ITEM RESPONSIBILITIES AND RIGHTS
------------------------------------------ -------------------------------------------------------------------------------------
LB CUSTOMER(1)
---------------------------------------- ----------------------------------------
- Provide shipping validation data if - Right to audit
requested by Customer
IN ALL CASES
- Provide inventory levels periodically
upon request by Customer
5.0 Production Specification - With the Customer determine and - With LB determine and approve the
approve the following Product following Product specification(s) as
specification(s) as required: required:
- Drug substance (including testing - Drug substance (including testing
performed on fermenter contents for performed on fermenter contents for
adventitious agents) adventitious agents)
- Drug product - Drug product
- Bulk placebo - Bulk placebo
- Filled placebo - Filled placebo
6.0 Production and Process Control - Make available for review by Customer - Right to review
documents relating to facility,
equipment, Process and test methods,
and GMP systems
- Jointly review and approve Process - Jointly review and approve Process
descriptions descriptions
- Define and perform an in-process - Agree in-process testing strategy
control and testing program
- Using LB templates prepare master - Right to review and comment on master
batch records for each processing batch records
step and provide to Customer for
review and comment. Retain final
master batch record on site at LB
- Designate unique batch numbers for - Right to audit
raw materials, process materials and
Product
- Manufacture of Product in accordance - Right to audit
with Product Specifications, cGMP
standards, batch records, in-process - Relevant sections of Customer's
controls and in-process regulatory submissions to be made
specifications available to LB as appropriate
- Ensure QA representatives on-site or - Right to audit
available at all times during
manufacture and testing of Product
CONFIDENTIAL TREATMENT
4
ITEM RESPONSIBILITIES AND RIGHTS
------------------------------------------ -------------------------------------------------------------------------------------
LB CUSTOMER(1)
---------------------------------------- ----------------------------------------
- Permit Customer's person on plant to - Right to designate 1 of its employees
be present in LB's facility during or consultants as Customer's person
normal business hours to observe the on plant, to be present in LB's
Runs and observe LB's performance, at facility during normal business times
times and for durations to be agreed. and for durations to be agreed. While
While at LB's facility, Customer's at LB's hours to observe the Runs and
representative shall comply with all observe LB's facility, Customer's
of LB's applicable policies and representative shall comply with
procedures, and, at LB's option, performance, at all LB's applicable
shall be escorted by LB personnel policies and procedures, and, at LB's
option, shall be escorted by LB
personnel
- Perform Product changeover testing of - Review and comment on LB's policy for
Product-contacting equipment in Product changeover testing of
accordance with LB policy Product-contacting equipment
7.0 Product Storage, Labeling and - Store, label and package the Product - Right to audit
Packaging Prior to Shipment (including samples) as defined in the
Product Specification - Provide information on shipping
requirements
8.0 Shipment Requirements - Ship Product on behalf of Customer to - Jointly agree with LB on process for
locations designated by Customer in shipping requirements
accordance with jointly agreed
process for shipping requirements - Right to audit
- Provide shipping validation data for - Acknowledge receipt of Product
Product if requested by Customer
- Right to audit
9.0 Laboratory Controls (QC) - Perform Product release testing - Right to audit
against Product Specifications
- Jointly agree on SOP's describing - Jointly agreed on SOP's describing
Product-specific analytical testing Product-specific analytical testing
methods methods
- Provide LB with Product-specific
information as it relates to sample
storage, handling and testing
requirements
- Retesting, where required, will be - Review and comment on LB retest
performed in accordance with LB's procedure. Review OOS reports;
retest procedure. Out of comment on corrective and
specification (OOS) Product preventative actions
CONFIDENTIAL TREATMENT
5
ITEM RESPONSIBILITIES AND RIGHTS
------------------------------------------ -------------------------------------------------------------------------------------
LB CUSTOMER(1)
---------------------------------------- ----------------------------------------
release testing results will be notified
to the Customer as soon as possible
within 3 business days of the OOS being
confirmed
- Send samples to Customer for - Perform Product potency testing and
additional testing (including potency provide data to LB; such data will be
testing) in accordance jointly provided for with LB's information
approved SOP only and not for inclusion into LB's
information only and not for
inclusion into LB's Certificate of
Analysis. Customer to create
Certificate of Analysis for potency
testing results. [Note from Trubion:
This text to clarify that Trubion is
performing the potency testing and
providing the results to LB `FOR
INFORMATION']
- Retain representative samples of bulk - Right to audit
Product from each batch in accordance
with LB SOP
- If requested by Customer, provide - Right to receive copies of raw data
copies of raw data and testing and testing records
records
- Take additional representative - Request additional samples to be
samples if requested and ship to shipped as required
Customer
- Prepare and characterise Product - Jointly approve Product reference
reference standard in accordance with standard Protocol
jointly agreed Protocol, if requested
by Customer - Right to audit
- Jointly approve Product reference - Jointly approved Product reference
standard report standard report
10.0 Use of Contract Testing - Qualify Contract Testing Laboratories - Right to jointly audit
Laboratories for Product release testing in
accordance with LB policy
- Notify Customer of Contract Testing - Consent or reject to the proposed use
Laboratories intended to be used for of Contract Testing Laboratories
Product release testing
- Facilitate audit by Customer if - Right to audit
requested from time to time
CONFIDENTIAL TREATMENT
6
RESPONSIBILITIES AND RIGHTS
------------------------------------------------------------------------
ITEM LB CUSTOMER(1)
-------------------------------- -------------------------------------- -------------------------------
- If not prohibited by - Right to request, receive
Contract Testing and use copies of LB's
Laboratory, provide audits of Contract Testing
Customer with copies of Laboratories when possible,
LB's audits of Contract unless prohibited by
Testing Laboratories when Contract Testing
possible, if requested Laboratories
11.0 Product Release and Lot - Review batch record for - Right to review completed
Review compliance with cGMP, and reviewed Product batch
manufacturing controls, and records
with the Product
Specifications
- Provide Customer with a - Right to review
copy of the Process
documentation including,
main operational steps from
the completed batch
record. This will include
Product analysis, a summary
of batch related deviations
and environmental
monitoring summaries, as
well as process data, as
requested
- If requested by Customer, - Right to request and
send full copies of actual receive full copies of
deviations actual deviations
- Prepare manufacturer's - Prepare Certificate of
Certificate of Analysis, Analysis and Certificate of
including related Compliance for release of
Certificate of Compliance product for use in human
clinical trials
- Release or reject Product - Release of reject Product
for use in human clinical
trials
12.0 Deviations and Failed - Initiate investigations, - Right to audit
Run Investigations and evaluate and define follow
Reports up actions and final
approval of deviations and
failure investigations
- Notify Customer of all - Review significant
significant deviations deviations; comment on
immediately and within at corrective and preventative
least 3 business days of actions
the event being assigned as
significant, and send
Customer the related
documentation. (A
significant deviation is
defined in standard
operating procedure 3150)
- Notify Customer of failed - Review failure
runs immediately and within investigation report and
at least 3 business days of comment on corrective and
failure being identified preventative actions
CONFIDENTIAL TREATMENT
7
RESPONSIBILITIES AND RIGHTS
------------------------------------------------------------------------
ITEM LB CUSTOMER(1)
-------------------------------- -------------------------------------- -------------------------------
- Immediately and within at least 3
business days of event being
identified, notify Customer of any
events which may impact batches
previously shipped or released
13.0 Change Control - Jointly agree on SOP for - Jointly agree SOP for
Procedures change control procedures change control procedures
between the 2 companies between the 2 companies
that describes the intended that describes the intended
use of each company's use of each company's
independent change control independent change control
system systems
CUSTOMER PROPOSED CHANGES
- Process Product-specific - Propose Customer
change through change Product-specific changes
control and notify Customer and provide rationale in
of change approval. If writing
change rejected, discuss
reasons for rejection with
Customer
- Approve proposed
Product-specific changes
prior to implementation
LB PROPOSED CHANGES
- Proposed Product-specific - Process Product-specific
changes and provide change through change
rationale for change to control and notify LB of
process descriptions; test change approval. If change
methods; sampling plans; rejected, discuss reasons
specifications for key raw for rejection with LB
materials (animal and / or
human derived raw - Approve proposed
materials, chromatography Product-specific changed
resins and final prior to implementation
formulation excipients);
Product specification(s)
and stability programme,
in-process controls and
other key processing steps
- Inform Customer of changes - Right to audit
to key personnel as
identified in Appendix 1
- Inform Customer of changes - Right to audit
to major items of
equipment, premises and
utilities used for
manufacture of Product
ALL CHANGES
- With Customer define - With LB define strategy for
strategy for notifying change to
Regulatory
CONFIDENTIAL TREATMENT
8
RESPONSIBILITIES AND RIGHTS
------------------------------------------------------------------------
ITEM LB CUSTOMER(1)
-------------------------------- -------------------------------------- -------------------------------
notifying change to Regulatory Agency as appropriate
Agency as appropriate (see Section (see Section 20.0, below,
20.0, below, Regulatory Regulatory Submissions)
Submissions)
- Inform Customer of Product - Ensure Product is not
batches manufactured with distributed until
the change until regulatory Regulatory approval
approval obtained, if obtained, if required
required
- Cooperate with Customer in - Cooperate with LB in
connection with change connection with change
controls; respect controls; respect LB's
Customer's change controls, change controls, and, as
and, as appropriate, use it appropriate, use it to
to initiate LB's change initiate Customer's change
controls controls
14.0 Reprocessing / Rework - Processing to be performed - Review and comment on LB's
in accordance with LB SOP. reprocessing / rework SOP;
With Customer agree on with LB agree on
reprocessing / rework reprocessing / rework
procedures, where possible procedures, where possible
prior to execution prior to execution
- Provided documented reason - Right to audit
and justification for
reprocessing / rework event
- With the Customer agree on - With LB agree the
the appropriate testing appropriate testing
required prior to Product required prior to Product
release release
15.0 Audit - Permit Customer - Provide reasonable notice
representatives access as of intention to audit
reasonably required to
conduct a cGMP compliance - Right to 2 standard cGMP
audit, including access to compliance audits per year,
warehousing, manufacturing plus right to additional
areas, laboratories, and "for cause" audits
manufacturing records and
documents, including SOPs - Right to audit each batch
(unless they contain record
specific LB proprietary
information eg media - Hold an exit meeting to
formulations), and discuss observations
personnel, for audit
purposes. Customer - Provide an audit report
representatives to be within 30 days of
accompanied at all times by completion of audit
LB personnel
- Two standard cGMP
compliance audits permitted
per year, with an audit not
to exceed 3 working days
and 2 groups of auditors.
Additionally the Customer may
CONFIDENTIAL TREATMENT
9
RESPONSIBILITIES AND RIGHTS
------------------------------------------------------------------------
ITEM LB CUSTOMER(1)
-------------------------------- -------------------------------------- -------------------------------
request "for cause"
audits to address
production of Product
quality issues
- One 2 day audit for each
batch record if requested
by Customer
- Allow the Customer to
observe operations related
to Product manufacturing
and testing providing other
Customer's confidentiality
is respected
- Provide a written response to all
audit findings that require
corrective action within 30 days of
receipt of the audit report.
Response to include expected
timelines
16.0 Product Complaints and - Respond to requests for - Receive and investigate
Recall data to assist Customer in Product complaints and
their investigation. Agree instigate Product recall as
a time scale for response appropriate
17.0 Batch Records - Retain records associated - Right to audit
with manufacture and
testing records of Product
including records
associated with the
inspection and release of
raw materials and primary
packaging components of the
Product for 5 years from
the date of manufacture of
Product. Date of
manufacture is defined as
the date Product is
dispensed in to the bulk
product container)
- Notify Customer of intent - Customer to approve
to destroy records with destruction or request
option to send records to receipt of records
Customer
18.0 Process Validation / - With Customer define - With LB define process
Stability Studies process validation plans validation plans for
for Product including Product including
analytical validation and analytical validation and
stability studies stability studies
WHERE PROCESS VALIDATION IS
PERFORMED BY LB
- Provide Customer with - Approve Product specific
Product specific validation validation protocol(s)
protocol(s) for including stability protocols
CONFIDENTIAL TREATMENT
10
RESPONSIBILITIES AND RIGHTS
-------------------------------------------------------------------------------
ITEM LB CUSTOMER(1)
---------------------- ---------------------------------------- ------------------------------------
approval prior to execution
- Provide Customer with draft - Review and comment on Product
Product specific validation report(s) specific validation report(s)
for review and comment including stability reports
- Issue Customer with copy of -
final Product specific validation
report(s)
WHERE PROCESS VALIDATION IS
PERFORMED BY CUSTOMER
- Incorporate specifications in - Provide LB with process
cGMP documentation and regulatory validation reports
submissions
19.0 Regulatory Agency GMP INSPECTIONS
Inspection
- Inform Customer of Regulatory - For Regulatory Agency inspections
Agency inspections or regulatory or regulatory action affecting
action affecting manufacture, testing Product, provide assistance
or storage of Product when requested by LB
- Notify Customer of inspection - Comment on proposed inspection
observations (including Deficiency responses to observations
Letters) affecting the Product, relevant to Product
process or systems relating to the
Product
20.0 Regulatory WHERE A DATA PACK IS PROVIDED BY LB TO
Submissions SUPPORT CUSTOMER'S CLINICAL TRIAL
APPLICATION
INITIAL APPLICATION, AMENDMENTS AND
RESPONSES TO QUESTIONS
- Provide Customer with data pack - Prepare and provide LB with
covering activities performed by LB copy of relevant sections of
clinical trial application for
- Review and comment on relevant review and comment prior to
sections of clinical trial submission to Regulatory Agency
application
- Provide LB with copy of relevant
sections as submitted to
Regulatory Agencies
TELECONFERENCES AND MEETINGS WITH THE
REGULATORY AGENCIES
- Attend teleconferences and - Arrange for LB personnel to have
meetings between the Customer and option to attend teleconferences
Regulatory Agencies arranged and meetings between Customer
CONFIDENTIAL TREATMENT
11
RESPONSIBILITIES AND RIGHTS
-------------------------------------------------------------------------------
ITEM LB CUSTOMER(1)
---------------------- ---------------------------------------- ------------------------------------
to specifically discuss topics and Regulatory Agencies to
relating to LB's responsibilities specifically discuss topics
relating to LB's responsibilities
CONFIDENTIAL TREATMENT
12
QUALITY APPROVAL
LONZA BIOLOGICS PLC
Name: /s/ Xxxx Imwinkleried Signature: /s/ Xxxx Imwinkleried
-------------------------- --------------------------
Title: Senior Vice President Date: (illegible) Apr 2004
TRUBION PHARMACEUTICALS INC.
Name: Xxxxx X. Xxxxxxxx, MD Signature: /s/ Xxxxx Xxxxxxxx
--------------------------
Title: President & CEO Date: 4/23/2004
CONFIDENTIAL TREATMENT
13
APPENDIX 1 TO THE QUALITY AGREEMENT
CUSTOMER LONZA
SENIOR VICE PRESIDENT, HEAD OF LONZA CONTRACT MANUFACTURING:
RESEARCH AND DEVELOPMENT:
Xxxxxxx X Xxxxxx PhD Mr Rene Imwinkleried
Senior Vice President Head of Lonza Contract Manufacturing
Research and Development Lonza Biologics
Trubion Pharmaceuticals Inc 000 Xxxx Xxxx
2401 Fourth Avenue, Suite 1050 Slough SL1 4DX
Xxxxxxx, XX 00000 XX
XXX
Tel:x0 000 000 0000 Tel:x00 0000 000000
Fax: x0 000 000 0000 Fax: x00 0000 000000
Email: xxxx0xx@xxxxxxx.xxx Email: Xxxx.lmwinkleried@Lonza,com
HEAD OF QUALITY: HEAD OF QUALITY:
Xxxxx X Xxxxx Xxx Xxxxxxx Xxxxxx
Senior Director, Regulatory Affairs Head of Quality and Regulatory Affairs
Trubion Pharmaceuticals Inc Lonza Biologics
0000 Xxxxxx Xxxxxx, Xxxxx 0000 000 Xxxx Xxxx
Xxxxxxx, XX 00000 Xxxxxx XX0 0XX
XXX XX
Tel:x0000 000 0000 Tel:x00 0000 000000
Fax:x0 000 000 0000 Fax;x00 0000 000000
Email: xxxxxx@xxxxxxx.xxx Email: Xxxxxxx.Xxxxxx@Xxxxx.xxx
HEAD OF MANUFACTURING: DIRECTOR OF MANUFACTURING, UK:
Xxxx X Xxxxx Xx Xxxxxxx X Xxxxx
Vice President, Development Head of Manufacturing
Trubion Pharmaceuticals Inc Lonza Biologics
0000 Xxxxxx Xxxxxx, Xxxxx 0000 000 Xxxx Xxxx
Xxxxxxx, XX 00000 Xxxxxx XX0 0XX
XXX XX
Tel: x0 000 000 0000 Tel: x00 0000 000000
Fax: x0 000 000 0000 Fax: x00 0000 000000
Email: xxxxxx@xxxxxxx.xxx Email: Xxxx.Xxxxx@Xxxxx.xxx
QUALITY CONTROL MANAGER: QUALITY CONTROL MANAGER:
Xxx Xxx PhD Xx Xxxxx Xxxxxxx
Director, Product Development Head of QC and Analytical
Trubion Pharmaceuticals Inc Lonza Biologics
0000 Xxxxxx Xxxxxx, Xxxxx 0000 000 Xxxx Xxxx
Xxxxxxx, XX 00000 Xxxxxx XX0 0XX
XXX XX
Tel: x0 000 000 0000 Tel: x00 0000 000000
Fax: x0 000 000 0000 Fax: x00 0000 000000
Email: xxxx@xxxxxxx.xxx Email: Xxxxx.Xxxxxxx@Xxxxx.xxx
CONFIDENTIAL TREATMENT
14
SCHEDULE 5
SPECIAL TERMS
OUTLINE OF TERMS FOR THE TECHNOLOGY TRANSFER OF THE PROCESS FOR
MANUFACTURE OF PRODUCT TO CUSTOMER OR TO A THIRD PARTY
This Schedule 5 is the Schedule that is referred to in Clause 9.9 of the
Development and Manufacturing Services Agreement ("Development and Manufacturing
Services Agreement") between LONZA BIOLOGICS PLC as "LB" and TRUBION
PHARMACEUTICALS, INC. as "Customer" related to the Technology Transfer of the
Process to Customer or a third party. This Schedule 5 sets forth some additional
commercial terms for any Technology Transfer. All capitalized terms used but not
defined in this Schedule 5 shall have the meanings given in the Development and
Manufacturing Services Agreement.
***
CONFIDENTIAL TREATMENT
1
